Controversies in the Management of Intermediate-Risk Differentiated Thyroid Cancer

This comprehensive review examines the current controversies regarding diagnosis and management of intermediate risk differentiated thyroid cancer (DTC). The evolution of risk stratification systems is discussed, highlighting limitations such as heterogeneity in patient cohorts, variability in outcome definitions, and the need for more precise risk estimation tools incorporating genetic profiles and individual risk modifiers. The role of radioactive iodine (RAI) therapy in intermediate-risk DTC is examined, considering evolving evidence, conflicting study results, and the necessity for personalized treatment decisions based on risk modifiers, potential morbidity, and patient preferences. Furthermore, the shift from total thyroidectomy to lobectomy in certain intermediate-risk cases is explored, emphasizing the need for tailored surgical approaches and the impact on long-term outcomes, recurrence rates, and quality of life. This review underscores the importance of ongoing research, prospective trials, and interdisciplinary collaboration to address these complexities and advance personalized management strategies for patients with intermediate-risk DTC.